Impact of transcatheter valve implantation versus surgical valve replacement on aquired von Willebrand syndrome and platelet function in patients with aortic stenosis

• Conditions: I35.0; D68.01; Aortic (valve) stenosis

• Registration Number: DRKS00012910
• Lead Sponsor: niversitaets-Herzzentrum Freiburg Bad Krozingen Klinik für Kardiologie und Angiologie II

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2016-08-16
• Study Start: 2017-10-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Indication for aortic valve replacement (bioprosthetic valve/CoreValve®/Edwards Sapien®), age > 60 years, written informed consent

Exclusion Criteria

Prior valvular interventions or cardiac surgery, known severe disorder of the coagulation system, known hematologic disease, severe hepatopathy, hemodialysis, contraindication for treatment with TAVI, peri- or postinterventional transfusions of fresh frozen plasma (FFP), platelets or coagulation factors

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fraction of large von Willebrand Factors (vWF) multimeres using western blot at day one and day six after aortic valve replacement

Secondary Outcome Measures

Name	Time	Method
Reticulated platelet count (Sysmex XE-2100™), platelet reactivity (Multiplate® Analyzer) and platelet microparticles (Flow cytometry) at day one and day six after aortic valve replacement